Research programme: m6A regulating molecules - Racura Oncology
Alternative Names: N6-methyladenosine regulating molecules - Racura OncologyLatest Information Update: 22 Dec 2025
At a glance
- Originator Race Oncology
- Developer Racura Oncology
- Class Antineoplastics
- Mechanism of Action RNA modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 01 Dec 2025 Race Oncology is now called Racura Oncology (Racura Oncology website, December 2025)
- 13 Jul 2023 Early research in Cancer in Australia (unspecified route) (Race Oncology pipeline, July 2023)